Presentation is loading. Please wait.

Presentation is loading. Please wait.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

Published byHelinä Hovinen Modified over 5 years ago

Similar presentations

Presentation on theme: "Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical."— Presentation transcript:

1 Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse.
Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. A, A summary of each patient's (n = 49) treatment regimen along with results of serial plasma samples (n = 208) analyzed. B, A summary table of patients by breast cancer subtype, number of relapsed patients, percentage detected by ctDNA analysis, and the median lead time in days. PPV, positive-predictive value [True Positive/(True Positive + False Positive)]; NPV, negative-predictive value [True Negative/(False Negative + True Negative)]. C, A comparison of molecular and clinical relapse by breast cancer subtype, HR+/HER2− (dark blue), HER2+ (green), and TNBC (orange) using the paired Wilcoxon signed-rank test (P < 0.001). Raoul Charles Coombes et al. Clin Cancer Res 2019;25: ©2019 by American Association for Cancer Research

Download ppt "Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical."

Similar presentations

The expression and signaling of FGFR3 in WM cells.

The expression and signaling of FGFR3 in WM cells.
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.

S4 Fig. REMARK diagram of course selection for analysis of ctDNA pre-treatment and for ctDNA change after the first and second cycle of chemotherapy. Courses.
High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.
Rearrangements of Gene A and Gene B

Rearrangements of Gene A and Gene B
سرطان الثدي Breast Cancer

سرطان الثدي Breast Cancer
CD25 expression is associated with unfavorable clinical outcome.

CD25 expression is associated with unfavorable clinical outcome.
Large-scale testing of women in Copenhagen has not reduced the prevalence of Chlamydia trachomatis infections  H. Westh, H.J. Kolmos  Clinical Microbiology.

Large-scale testing of women in Copenhagen has not reduced the prevalence of Chlamydia trachomatis infections  H. Westh, H.J. Kolmos  Clinical Microbiology.
Figure 1. Table for calculating the accuracy of a diagnostic test.

Figure 1. Table for calculating the accuracy of a diagnostic test.
Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.
Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,

Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,
Clinical applications of CTC and ctDNA analyses in cancer care.

Clinical applications of CTC and ctDNA analyses in cancer care.
Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.
Volume 24, Issue 8, Pages (August 2018)

Volume 24, Issue 8, Pages (August 2018)
Schematic of screening program for diabetes mellitus (DM) during acute myocardial infarction (AMI). Schematic of screening program for diabetes mellitus.

Schematic of screening program for diabetes mellitus (DM) during acute myocardial infarction (AMI). Schematic of screening program for diabetes mellitus.
Figure 1 BG-12 treatment reduced total circulating B cells and had variable effects on memory B cells BG-12 treatment reduced total circulating B cells.

Figure 1 BG-12 treatment reduced total circulating B cells and had variable effects on memory B cells BG-12 treatment reduced total circulating B cells.
Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment. Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment.

Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment. Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment.
Expression analysis of IGFBP-3 using human whole-genome microarray.

Expression analysis of IGFBP-3 using human whole-genome microarray.
A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),
FAK overexpression in invasive human breast cancer and DCIS

FAK overexpression in invasive human breast cancer and DCIS

Similar presentations

Ads by Google